Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have earned an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $324.1111.

KRYS has been the topic of a number of recent research reports. Chardan Capital upped their target price on shares of Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Evercore reiterated an “outperform” rating and issued a $300.00 price target on shares of Krystal Biotech in a research note on Tuesday, May 5th. Jefferies Financial Group increased their price objective on shares of Krystal Biotech from $310.00 to $371.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Wolfe Research began coverage on shares of Krystal Biotech in a report on Friday, March 27th. They issued a “peer perform” rating on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and set a $310.00 price objective on shares of Krystal Biotech in a research report on Monday, June 1st.

Krystal Biotech Trading Up 2.6%

Shares of NASDAQ KRYS opened at $309.75 on Wednesday. The stock has a market cap of $9.13 billion, a P/E ratio of 41.41 and a beta of 0.53. The business’s fifty day simple moving average is $284.68 and its 200-day simple moving average is $266.01. Krystal Biotech has a 12-month low of $127.99 and a 12-month high of $319.48.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.45 by $0.38. The firm had revenue of $116.36 million during the quarter, compared to analysts’ expectations of $112.11 million. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%. On average, equities analysts forecast that Krystal Biotech will post 7.83 EPS for the current fiscal year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $308.11, for a total transaction of $7,702,750.00. Following the completion of the sale, the insider directly owned 1,378,155 shares of the company’s stock, valued at $424,623,337.05. The trade was a 1.78% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP John Charles Thomas sold 642 shares of the company’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total value of $193,903.26. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Krystal Biotech

Several hedge funds have recently added to or reduced their stakes in the stock. Bessemer Group Inc. boosted its holdings in shares of Krystal Biotech by 106.9% in the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock valued at $26,000 after buying an additional 77 shares in the last quarter. Sound Income Strategies LLC grew its position in shares of Krystal Biotech by 1,270.0% in the 4th quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock valued at $34,000 after buying an additional 127 shares during the last quarter. Western Wealth Management LLC acquired a new stake in Krystal Biotech during the 1st quarter worth $34,000. Greenline Wealth Management LLC acquired a new stake in Krystal Biotech during the 4th quarter worth $34,000. Finally, Danske Bank A S purchased a new stake in Krystal Biotech in the third quarter valued at $35,000. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.